Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Discover why Johnson & Johnson is a top stock pick for income investors in 2025 with strong sales growth and promising earnings outlook.
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the ...
Why Johnson & Johnson (JNJ) Surged on Monday
The S&P 500 and Nasdaq both fell by a whopping 1.46 percent and 3.07 percent, respectively, over fears that China is ...
J&J Tops Quarterly Profit Estimates on Cancer Drug Sales
Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...
Balanced Expectations Amid Challenges and Opportunities for Johnson & Johnson: Hold Rating Issued
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...
Morningstar8d
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Medical-technology and drug company's 2025 sales outlook is below consensus Johnson & Johnson's stock ... from Dow Jones Newswires and The Wall Street Journal. Chip stocks and other AI-related ...